Nasdaq confirms Alaunos has regained stockholders' equity compliance, cancels hearing

Alaunos Therapeutics disclosed in an 8-K dated October 22, 2026 that Nasdaq has confirmed the company regained compliance with its minimum stockholders' equity rule. On October 22, 2026, the Company received a letter from Nasdaq's Office of General Counsel advising that the Staff has confirmed that the Company has regained compliance with the Stockholders' Equity Requirement.¹ As a result, Nasdaq has determined that this matter is now closed, the hearing before the Panel scheduled for November 10, 2026 has been cancelled, and the Company's common stock will continue to be listed and traded on The Nasdaq Capital Market.¹

The compliance issue traced back to an April 9, 2026 Nasdaq deficiency letter. That notice informed the company it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders' equity for continued listing.¹ On October 5, 2026, Nasdaq warned the company its securities were subject to delisting due to continued non-compliance unless it timely requested a hearing before the Nasdaq Hearings Panel.¹ The company timely requested a hearing before the Panel, which was scheduled for November 10, 2026.¹

Alaunos had previously said it believed it fixed the deficiency through a financing. As disclosed in the company's Form 8-K filed October 21, 2026, the company believed that, as a result of the completion on October 14, 2026 of its previously announced private placement financing, it had regained compliance with the Stockholders' Equity Requirement.¹ That filing had also noted that Fairmount Healthcare Fund II, which led the financing, waived a cash settlement right on a portion of its preferred shares, helping support the equity calculation.